Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Rare Diseases

Syndrome

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Preleukemia

Myelodysplastic Syndromes

Neoplasms by Histologic Type

Hematologic Diseases

Bone Marrow Diseases

Precancerous Conditions

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Antineoplastic Agents

All Drugs and Chemicals

Venetoclax

Azacitidine

Phase I, 6MW3811 monotherapy in 2 dose levels of 30mg/kg or 45mg/kg; phase II, 6MW3811 will be given in combination with AZA( cohort1) and AZA plus VEN(cohort 2)

phaseI: 6MW3211 will be administered in 30mg/kg and 45mg/kg intravenously once every 2 weeks; phaseII: 6MW3211 will be administered in 45mg/kg intravenously in both 2 cohorts.AZA will be administered in 75mg/m2 by subcoutaneous injection in cohort 1 as well as cohort 2 from Day1-Day7 every 28-day cycle. VEN will be administered orally with dose escalation to 400mg daily every cycle.

6MW3211 injection with Intravenous Infusion

Hu Zhou, Ph.D

Hu Zhou, Ph.d

This study is aimed to evaluate the efficacy, safety, immunogenicity and pharmkinetics, pharmacodynamics of 6MW3211 as monotherapy and in combination with AZA or AZA plus VEN in patients with AML/MDS.

This study is a phase I/II study to evaluate the pharmacokinetics, pharmacodynamics, efficacy and safety of 6MW3211 monotherapy or combined with AZA or AZA plus VEN in patients with AML and MDS. There will be 2 parts of this study. The phase Ib is about monotherapy of 6MW3211 and Phase II is designed to evaluate the safety and efficacy of 6MW3211 combined with AZA or AZA plus VEN in patients with relapse/refractory and newly diagnosed AML and MDS.

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

A Study to Evaluate Pharmcokinetics, Pharmacodynamics , Efficacy and Safety of 6MW3211 Monotherapy and in Combination With Azacitidine(AZA) or AZA Plus Venetoclax(VEN) in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

to evaluate the percentage of participants with adverse events and serious adverse events of 6MW3211 combination therapy in AML and MDS

Mabwell (Shanghai) Bioscience Co., Ltd.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS	NCT05448599	Acute Myeloid L... Myelodysplastic...	6MW3211 injecti...	18 Years - 75 Years	Mabwell (Shanghai) Bioscience Co., Ltd.
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS	NCT05448599	Acute Myeloid L... Myelodysplastic...	6MW3211 injecti...	18 Years - 75 Years	Mabwell (Shanghai) Bioscience Co., Ltd.

Spots Global Cancer Trial Database for 6mw3211 injection with intravenous infusion